制药业务表现强劲，是增长的主要驱动力，特别是在中国市场的合同研发生产组织(CDMO)及生物技术 客户领域实现了超过20%的增长。质谱与液相色谱相关产品线增长显著。例如，Alliance液相色谱仪销 售额同比增长270%，Xevo TQ Absolute质谱仪(用于PFAS检测)年增长40%。公司持续将约10%的产品销 售额投入研发。在生物分离和生物分析表征等相邻领域表现亮眼，其中生物分离业务年增长达50%。印 度市场业务也实现了高teen百分比的增长。 战略推进 公司对BD(Becton Dickinson)生物科学和诊断业务的收购已按计划完成，预计将带来显著的协同效应， 包括未来3年内约2亿美元的成本协同。管理层为2026年设定了清晰的增长框架，预计仪器更换周期(处 于6年周期中期)将贡献低个位数增长，叠加GLP-1检测、PFAS检测、印度基因检测等特殊驱动因素(合 计贡献约200个基点)，新产品(如电荷检测质谱仪CDMS)也将推动增长。公司聚焦于生物制剂、诊断、 电池测试等高增长终端市场，目标未来五年收入复合年增长率达到7%(高于行业平均的4%)，并计划实 现约450个基点的利润率扩张。 以上内容基于公开 ...

Core Viewpoint - Waters Corporation launched the Xevo TQ Absolute XR mass spectrometer at ASMS 2025, featuring StepWave XR technology that enhances sensitivity and contamination resistance, aiding in PFAS detection and compliance with environmental regulations while optimizing energy consumption and space utilization [1][2]. Innovation Technology Highlights - StepWave XR ion guide technology offers 6 times the performance robustness compared to the previous Xevo TQ Absolute, with a continuous analysis duration increase of 6 times, successfully validated through 12,000 pesticide samples in fish feed, and improved contamination resistance [4][5]. - The instrument significantly reduces downtime, with customer evidence showing over 20,000 plasma sample injections maintaining reproducibility [5]. - Designed specifically for PFAS and genotoxic impurities, the quantification capability for negatively ionized compounds has been enhanced [5]. Environmental/Green Efficient Laboratory Solutions - Energy consumption and nitrogen usage have been reduced by 50%, with heat emissions also decreased by 50% [6]. - The compact design reduces the footprint by 50% [6]. Core Application Scenarios - PFAS Detection: The system is ready for quantitative analysis, meeting the latest EPA regulatory requirements [7]. - Pharmaceutical Quantitative Analysis: Achieves ultra-high sensitivity analysis of trace drug molecules in complex matrices, accelerating new drug development [7]. - High-Throughput Scenarios: Supports pharmaceutical companies, CROs, and government laboratories, with a 30% increase in daily sample throughput, validated by Synexa with over 20,000 injections [7]. - User Feedback: The Scientific Director of Synexa Life Sciences highlighted the Xevo TQ Absolute XR's reproducibility and accuracy in addressing emerging bioanalytical challenges, having completed over 20,000 plasma sample analyses in conjunction with the ACQUITY™ Premier UPLC™ system [7].

然而，LLE的缺点也很明显。一方面，水样中的颗粒物或溶解性有机物容易引发乳化现象，这就需要额外的离心或盐析 步骤，导致处理时间延长；另一方面，极大的溶剂消耗量（1 L水样需2 0 - 1 0 0 mL溶剂）增加了环保成本。而且，短链 导读： 为此，本文特别邀请了哈尔滨工业大学（深圳）的陈白杨教授团队，就PFAS检测中固相萃取与液液萃取技术进行深入解读。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在检测水中全氟和多氟烷基物质（PFAS）时，选择恰当的样品前处理方法极为关键。液相色谱（HPLC）常与固相萃 取（SPE）或液液萃取（LLE）相结合用于富集样品。这两种方法各有优缺点，要依据具体需求进行权衡选择。为此， 本文特别邀请了哈尔滨工业大学（深圳）的陈白杨教授团队，就PFAS检测中固相萃取与液液萃取技术进行深入解读。 (拓展阅读：专家解读|基于两步液液萃取前处理的离子色谱法检测水中全氟类物质) 固相萃取（SPE） SPE是一种高效的样品前处理技术，其过程为利用吸附剂选择性保留目标化合物，再用萃取剂高效解吸目标化合物。 SPE具有 ...